We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » First FDA Hearing on Reauthorizing BsUFA Shows Broad Support for Keeping Program
First FDA Hearing on Reauthorizing BsUFA Shows Broad Support for Keeping Program
The FDA’s first public meeting on the 2017 reauthorization of the Biosimilars User Fee Act brought calls for increased transparency in terms of how the agency regulates biosimilars and a rethinking of how these products will be named.